Literature DB >> 30423330

Risk of Second Primary Cancer in Survivors of In Situ Melanoma.

Michael G Kimlin1, Danny R Youlden2, Alison M Brodie3, Tracey DiSipio3, Philippa Youl3, Visalini Nair-Shalliker4, Peter D Baade5.   

Abstract

Survivors of invasive melanoma have an increased risk of developing second primary cancers; however, similar risks associated with in situ melanoma have not been established. We evaluated 39,872 survivors of first primary in situ melanoma diagnosed from 1982 through 2012 in Queensland, Australia. Relative risk of second nonmelanoma primary cancers was estimated from standardized incidence ratios with 95% confidence intervals. A total of 4,823 (12%) in situ melanoma survivors developed a second primary cancer. A small increased risk (6%) compared with the general population was found. In those younger than 50 years, risk was increased by 14% for all cancers combined. In situ melanoma survivors had significantly increased risks of developing lip, thyroid, pancreatic, and brain cancers and decreased risks of head and neck, and lung cancers. Male in situ melanoma survivors had a significantly increased risk of prostate cancer; female survivors had an increased risk of thyroid cancer and lymphoid leukemia. Findings indicate that in situ melanoma may predict the diagnosis of certain second primary cancers. This altered risk may be due to biological, behavioral, or genetic factors or increased medical surveillance, and it requires further investigation, particularly among people younger than 50 years.
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2018        PMID: 30423330     DOI: 10.1016/j.jid.2018.11.001

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  3 in total

1.  Clinical characteristics and overall survival nomogram of second primary malignancies after prostate cancer, a SEER population-based study.

Authors:  Yi Liu; Peipei Zhang; Yinghao Zhang; Lichuan Zheng; Wenbo Xu; Dongtao Hou; Zhengjun Kang
Journal:  Sci Rep       Date:  2021-01-14       Impact factor: 4.379

2.  Assessment of Trends in Second Primary Cancers in Patients With Metastatic Melanoma From 2005 to 2016.

Authors:  Weiye Deng; Yifan Wang; Xiangyu Liu; Jieqiong Liu; Liang Wang; Zhaogang Yang; Mingming Yang; Yi An; Chad Tang; Nina N Sanford; Betty Y S Kim; Wen Jiang
Journal:  JAMA Netw Open       Date:  2020-12-01

3.  Prostate cancer risk in patients with melanoma: A systematic review and meta-analysis.

Authors:  Prakash Acharya; Mahesh Mathur
Journal:  Cancer Med       Date:  2020-03-16       Impact factor: 4.452

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.